Aslan Fred sold $260K of ARTV

Aslan Fred (Chief Executive Officer) sold 62,178 shares of Artiva Biotherapeutics, Inc. (ARTV) at $4.18 ($0.26M total) on 2026-11-02.

Original reporting
SEC EDGAR · Aslan Fred
Published Nov 3, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
medium confidence
Mentioned
$ARTV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The transaction is a primary disclosure but modest in size, offering limited trading impetus.

02

Market read

A small insider sale with limited market impact; traders may monitor for any follow‑up activity.

03

What to watch

The CEO retains a large stake (over 1.4M shares), indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: after-hours today

Background

Form 4 filing disclosed the CEO's open‑market sale of ARTV shares.

Company-level read

Ticker impact

$ARTVBearishMedium confidence
Context

CEO Aslan Fred sold 62,178 shares for $259,972, reducing his stake to 1,457,428 shares.

Expected impact

likely modest downward pressure as the market prices the insider sell

Evidence & confidence

Insider sales by a CEO can be viewed negatively, but the amount ($260K) is relatively small for a mid‑cap biotech, limiting impact.

Market effects

Minimal effect on the broader biotech sector; similar insider sales are common.

None

None

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm listed on NASDAQ under ARTV.

  • Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.